I

n a big boost for its immunotherapy franchise, Merck (MRK)  disclosed top-line results of a key lung cancer study that showed its Keytruda treatment delivered particularly promising results. And while complete findings of the late-stage trial will not be known until the spring, the news is already reworking the outlook for the intensely competitive horse race among drug makers battling to dominate lung cancer.

So what did Merck say?

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.